Quantcast

Posts related to ‘Drug companies’

Merck Close to 52-Week High After Earnings (MRK)

Posted: February 2, 2012 at 8:55 am

Merck & Company, Inc. (NYSE: MRK) is trading up after its earnings report.  With a high dividend yield of 4.4%, many investors are watching this despite a stance of little ...
Read Full Story »

Pfizer Sneaks By Earnings Estimates (PFE, MRK)

Posted: January 31, 2012 at 7:17 am

Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company's guidance may be getting in the way a bit.  The ...
Read Full Story »

FTC Sues To Block Omnicare/PharMerica Merger; Express/Medco Next? (OCR, PMC, MHS, ESRX, T)

Posted: January 27, 2012 at 5:31 pm

The Federal Trade Commission is suing to block the merger between Omnicare, Inc. (NYSE: OCR) and Pharmerica Corporation (NYSE: PMC), where Omnicare is seeking to acquire the rival pharmacy provider PharMerica.... It ...
Read Full Story »

High-Premium Biotech M&A Continues (AMGN, CELG, MITI, IBB)

Posted: January 26, 2012 at 5:08 pm

Thursday brought yet more merger and acquisition news in the ongoing buyout trends in the biotech sector.  Amgen Inc. (NASDAQ: AMGN) announced that it is going to acquire Micromet, Inc. (NASDAQ: ...
Read Full Story »

Risks Abound In Express Scripts & Medco Merger (MHS, ESRX, T, CHSI, MNA)

Posted: January 19, 2012 at 3:04 pm

The Medco Health Solutions Inc. (NYSE: MHS) and Express Scripts Inc. (NASDAQ: ESRX) merger saga is one which may go down in the financial history books for one of the ...
Read Full Story »

Pharma Value Beyond The Patent Expiration Cliff (PFE, MRK, BMY, TEVA, AMGN, GSK)

Posted: January 11, 2012 at 1:37 pm

The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp ...
Read Full Story »

The $1,000 Genome Finally Arrives (LIFE)

Posted: January 10, 2012 at 11:47 am

Personalized medicine is coming... if you can afford it.  The quest for the $1,000 genomic map has been a race and it appears to be closer and closer.  News is out ...
Read Full Story »

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

Posted: January 4, 2012 at 8:01 am

For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at least some of the same problems of Big Pharma players like ...
Read Full Story »

Top Biotech Stock Picks For 2012 (ARIA, DNDN, GILD, HGSI, ILMN, INCY, JAZZ, LIFE, THRX, IBB, XBI)

Posted: December 28, 2011 at 7:01 am

The biotech sector has seen its share of ups and downs in 2011 and prior years.  It is almost always the case that some of the top performing stocks each ...
Read Full Story »

ARIAD Secures Much-Needed Capital for Trials, Commercialization, and Growth (ARIA)

Posted: December 15, 2011 at 9:54 am

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is raising cash to help support the commercialization of ponatinib in patients with resistant or intolerant CML and additional clinical development of its investigational targeted ...
Read Full Story »

The ‘Double’ Call in Human Genome (HGSI)

Posted: December 12, 2011 at 9:04 am

Human Genome Sciences Inc. (NASDAQ: HGSI) is not getting much of a boost despite being called as stock which could manage to double in price over the next 18 months ...
Read Full Story »

Get Ready for a Pfizer Dividend Hike… A Holiday Gift From Big Pharma (PFE, MRK, WPI, TEVA)

Posted: December 8, 2011 at 11:14 am

We recently gave a full review of the DJIA components we expect to raise their dividend payouts in the weeks and months ahead.  Among those we expect to raise the ...
Read Full Story »

Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)

Posted: December 6, 2011 at 12:45 pm

Dendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment.  Unfortunately, PROVENGE sales ran slower than expected after the FDA took forever to ...
Read Full Story »

Winners as Pfizer Loses Lipitor Patent (PFE, TEVA, MYL, WPI)

Posted: November 29, 2011 at 11:28 am

Pfizer Inc. (NYSE: PFE) has a big day ahead of it.  While it has been known for years, it is a massive date: Lipitor goes off-patent and will have generic ...
Read Full Story »

Probing for Value in Big Pharmaceutical Stocks (JNJ, PFE, AZN, BMY, MRK)

Posted: November 21, 2011 at 1:47 pm

It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1 billion to fail to get the drug to market. Like ...
Read Full Story »